The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Cardiovascular and Cerebrovascular Events in Patients Treated for Human Immunodeficiency Virus Infection
Open accessAbstract
BACKGROUND: Metabolic abnormalities associated with human immunodeficiency virus (HIV) infection, including dysglycemia and hyperlipidemia, are increasingly prevalent, and there is concern about the possibility of an association with accelerated cardiovascular and cerebrovascular disease. METHODS: We conducted a retrospective study of the risk of cardiovascular and cerebrovascular disease among the 36,766 patients who received care for HIV infection at Veterans Affairs facilities between January 1993 and June 2001. RESULTS: For antiretroviral therapy, 70.2 percent of the patients received nucleoside analogues, 41.6 percent received protease inhibitors, and 25.6 percent received nonnucleoside reverse-transcriptase inhibitors for a median of 17 months, 16 months, and 9 months, respectively. Approximately 1000 patients received combination therapy with a protease inhibitor for at least 48 months, and approximately 1000 patients received combination therapy with a nonnucleoside reverse-transcriptase inhibitor for at least 24 months. Between 1995 and 2001, the rate of admissions for cardiovascular or cerebrovascular disease decreased from 1.7 to 0.9 per 100 patient-years, and the rate of death from any cause decreased from 21.3 to 5.0 deaths per 100 patient-years. Patient-level regression analyses indicated that there was no relation between the use of nucleoside analogues, protease inhibitors, or nonnucleoside reverse-transcriptase inhibitors and the hazard of cardiovascular or cerebrovascular events, but the use of antiretroviral drugs was associated with a decreased hazard of death from any cause. CONCLUSIONS: Use of newer therapies for HIV was associated with a large benefit in terms of mortality that was not diminished by any increase in the rate of cardiovascular or cerebrovascular events or related mortality. Fear of accelerated vascular disease need not compromise antiretroviral therapy over the short term. However, prolonged survival among HIV infected patients means that longer-term observation and analysis are required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D. J., & Cooper, D. A. (1998) · AIDS · doi:10.1097/00002030-199807000-00003 · Cited by 2,370
Changing patterns of mortality across Europe in patients infected with HIV-1
Mocroft, A., Vella, S., Benfield, T., Chiesi, A., Miller, V, Gargalianos, P., Monforte, A. D., Yust, I., Bruun, J., Phillips, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03201-2 · Cited by 1,270
The Efficiency of Cox's Likelihood Function for Censored Data
Efron, B. (1977) · Journal of the American Statistical Association · doi:10.1080/01621459.1977.10480613 · Cited by 1,228
Carr, A., Samaras, K., Chisholm, D. J., & Cooper, D. A. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03391-1 · Cited by 1,065
Grunfeld, C. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.74.5.1045 · Cited by 848
The Care of HIV-Infected Adults in the United States
Bozzette, S. A., Berry, S. H., Duan, N., Frankel, M. R., Leibowitz, A. A., Lefkowitz, D., Emmons, C.-A., Senterfitt, J. W., Berk, M. L., Morton, S. C., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812243392606 · Cited by 508
Self-citationHypertriglyceridemia in the acquired immunodeficiency syndrome
Grunfeld, C., Kotler, D. P., Hamadeh, R., Tierney, A., Wang, J., & Pierson, R. N. (1989) · The American Journal of Medicine · doi:10.1016/0002-9343(89)90225-8 · Cited by 437
Vascular complications associated with use of HIV protease inhibitors
Gallet, B., Pulik, M., Genet, P., Chedin, P., & Hiltgen, M. (1998) · The Lancet · doi:10.1016/s0140-6736(05)78643-8 · Cited by 253
Heath, K. V., Hogg, R. S., Chan, K. J., Harris, M., Montessori, V., O'Shaughnessy, M. V., & Montaner, J. S. G. (2001) · AIDS · doi:10.1097/00002030-200101260-00013 · Cited by 249
Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men
Hommes, M. J. T., Romijn, J. A., Endert, E., Schattenkerk, J. K. M. E., & Sauerwein, H. P. (1991) · Metabolism · doi:10.1016/0026-0495(91)90059-6 · Cited by 150
Vascular complications associated with use of HIV protease inhibitors
Vittecoq, D., Escaut, L., & Jj, M. (1998) · The Lancet · doi:10.1016/s0140-6736(05)78644-x · Cited by 107
HIV-1 Tat Induces Microvascular Endothelial Apoptosis Through Caspase Activation
Park, I.-W., Ullrich, C., Schoenberger, E. S., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.5.2766 · Cited by 80
Lenert, L. A., Feddersen, M., Sturley, A., & Lee, D. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01156-7 · Cited by 64
Jia, H., Löhr, M., Jezequel, S., Davis, D., Shaikh, S., Selwood, D. L., & Zachary, I. C. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4790 · Cited by 60
Huang, M., Hunter, M. G., & Bond, V. C. (1999) · AIDS Research and Human Retroviruses · doi:10.1089/088922299310160 · Cited by 57
Geffner, M. E., Yeh, D. Y., Landaw, E. M., Scott, M. L., Stiehm, E. R., Bryson, Y. J., & Israele, V. (1993) · Pediatric Research · doi:10.1203/00006450-199307000-00016 · Cited by 51
Backus, L. I., Mole, L. A., Chang, S. W., & Deyton, L. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00442-5 · Cited by 50
Self-citation
Cited by
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182776f83 · Cited by 2,410
Combination Antiretroviral Therapy and the Risk of Myocardial Infarction
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030218 · Cited by 1,678
Triant, V. A., Lee, H., Hadigan, C., & Grinspoon, S. K. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2190 · Cited by 1,613
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.013 · Cited by 1,555
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
Kitahata, M. M., Gange, S. J., Abraham, A. G., Merriman, B., Saag, M. S., Justice, A. C., Hogg, R. S., Deeks, S. G., Eron, J. J., Brooks, J. T., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807252 · Cited by 1,105
Metadata
- Authors
- Bozzette, S. A., Ake, C. F., Tam, H. K., Chang, S. W., & Louis, T. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-02-20
- Volume
- 348
- Issue
- 8
- Pages
- 702-710
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1979252165
- Cited by
- 625
- References
- 19
- FWCI
- 81.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.